Dr. Juan Carlos Silva is a biomedical scientist with a Ph.D. in Biosciences and over seven years of experience in translational immunology, oncology, and infectious disease research. His work integrates molecular biology, therapeutic antibody development, and vaccine design, focusing on immunomodulation and host–pathogen interactions. He has conducted research on Trypanosoma cruzi therapeutic vaccines, monoclonal antibody generation, and immune profiling. Currently a Postdoctoral Fellow at The University of Texas at El Paso, he develops diagnostic and therapeutic antibodies and peptide-based vaccines targeting immune regulatory pathways across cancer and inflammatory disease models.